| Dr Ioan Belovarski, MD, MPH | |
|
333 H St Ste 2080, Chula Vista, CA 91910-5558 | |
| (619) 662-4100 | |
| Not Available |
| Full Name | Dr Ioan Belovarski |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 7 Years |
| Location | 333 H St Ste 2080, Chula Vista, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316471451 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | A157748 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Johns Regional Medical Center | Oxnard, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cep America - California | 6103739131 | 954 |
News Archive
5N Plus Inc. announced today the closing of a new $250 million senior secured multi-currency revolving credit facility to replace its existing $50 million two-year senior secured revolving facility with National Bank of Canada.
A research team from the University of Liverpool has reached an important milestone towards creating a urine diagnostic test for prostate cancer that could mean that invasive diagnostic procedures that men currently undergo eventually become a thing of the past.
The most poisonous substance on Earth - already used medically in small doses to treat certain nerve disorders and facial wrinkles - could be re-engineered for an expanded role in helping millions of people with rheumatoid arthritis, asthma, psoriasis and other diseases, scientists are reporting. Their study appears in ACS' journal Biochemistry.
Researchers at the University of Oxford and Progenra, Inc. are pleased to announce the publication of a research article entitled "Activity-Based Chemical Proteomics Accelerates Inhibitor Development for Deubiquitylating Enzymes" that details a novel proteomics based method to detect inhibition of intracellular deubiquitylating enzymes (DUBs).
DARA BioSciences announced today grant approvals by the Internal Revenue Service under the Patient Protection and Affordable Care Act of 2010 for KRN5500 and DB959 in the amount of approximately $500,000 for the calendar year 2009.
› Verified 7 days ago
| Entity Name | Cep America - California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023063542 PECOS PAC ID: 6103739131 Enrollment ID: O20031106000520 |
News Archive
5N Plus Inc. announced today the closing of a new $250 million senior secured multi-currency revolving credit facility to replace its existing $50 million two-year senior secured revolving facility with National Bank of Canada.
A research team from the University of Liverpool has reached an important milestone towards creating a urine diagnostic test for prostate cancer that could mean that invasive diagnostic procedures that men currently undergo eventually become a thing of the past.
The most poisonous substance on Earth - already used medically in small doses to treat certain nerve disorders and facial wrinkles - could be re-engineered for an expanded role in helping millions of people with rheumatoid arthritis, asthma, psoriasis and other diseases, scientists are reporting. Their study appears in ACS' journal Biochemistry.
Researchers at the University of Oxford and Progenra, Inc. are pleased to announce the publication of a research article entitled "Activity-Based Chemical Proteomics Accelerates Inhibitor Development for Deubiquitylating Enzymes" that details a novel proteomics based method to detect inhibition of intracellular deubiquitylating enzymes (DUBs).
DARA BioSciences announced today grant approvals by the Internal Revenue Service under the Patient Protection and Affordable Care Act of 2010 for KRN5500 and DB959 in the amount of approximately $500,000 for the calendar year 2009.
› Verified 7 days ago
| Entity Name | Cep America - California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548667843 PECOS PAC ID: 6103739131 Enrollment ID: O20040121000458 |
News Archive
5N Plus Inc. announced today the closing of a new $250 million senior secured multi-currency revolving credit facility to replace its existing $50 million two-year senior secured revolving facility with National Bank of Canada.
A research team from the University of Liverpool has reached an important milestone towards creating a urine diagnostic test for prostate cancer that could mean that invasive diagnostic procedures that men currently undergo eventually become a thing of the past.
The most poisonous substance on Earth - already used medically in small doses to treat certain nerve disorders and facial wrinkles - could be re-engineered for an expanded role in helping millions of people with rheumatoid arthritis, asthma, psoriasis and other diseases, scientists are reporting. Their study appears in ACS' journal Biochemistry.
Researchers at the University of Oxford and Progenra, Inc. are pleased to announce the publication of a research article entitled "Activity-Based Chemical Proteomics Accelerates Inhibitor Development for Deubiquitylating Enzymes" that details a novel proteomics based method to detect inhibition of intracellular deubiquitylating enzymes (DUBs).
DARA BioSciences announced today grant approvals by the Internal Revenue Service under the Patient Protection and Affordable Care Act of 2010 for KRN5500 and DB959 in the amount of approximately $500,000 for the calendar year 2009.
› Verified 7 days ago
| Entity Name | Centro De Salud De La Comunidad De San Ysidro, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124782685 PECOS PAC ID: 6901709435 Enrollment ID: O20040130000711 |
News Archive
5N Plus Inc. announced today the closing of a new $250 million senior secured multi-currency revolving credit facility to replace its existing $50 million two-year senior secured revolving facility with National Bank of Canada.
A research team from the University of Liverpool has reached an important milestone towards creating a urine diagnostic test for prostate cancer that could mean that invasive diagnostic procedures that men currently undergo eventually become a thing of the past.
The most poisonous substance on Earth - already used medically in small doses to treat certain nerve disorders and facial wrinkles - could be re-engineered for an expanded role in helping millions of people with rheumatoid arthritis, asthma, psoriasis and other diseases, scientists are reporting. Their study appears in ACS' journal Biochemistry.
Researchers at the University of Oxford and Progenra, Inc. are pleased to announce the publication of a research article entitled "Activity-Based Chemical Proteomics Accelerates Inhibitor Development for Deubiquitylating Enzymes" that details a novel proteomics based method to detect inhibition of intracellular deubiquitylating enzymes (DUBs).
DARA BioSciences announced today grant approvals by the Internal Revenue Service under the Patient Protection and Affordable Care Act of 2010 for KRN5500 and DB959 in the amount of approximately $500,000 for the calendar year 2009.
› Verified 7 days ago
| Entity Name | Alvarado Emergency Medical Associates, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285811992 PECOS PAC ID: 0042396251 Enrollment ID: O20080328000280 |
News Archive
5N Plus Inc. announced today the closing of a new $250 million senior secured multi-currency revolving credit facility to replace its existing $50 million two-year senior secured revolving facility with National Bank of Canada.
A research team from the University of Liverpool has reached an important milestone towards creating a urine diagnostic test for prostate cancer that could mean that invasive diagnostic procedures that men currently undergo eventually become a thing of the past.
The most poisonous substance on Earth - already used medically in small doses to treat certain nerve disorders and facial wrinkles - could be re-engineered for an expanded role in helping millions of people with rheumatoid arthritis, asthma, psoriasis and other diseases, scientists are reporting. Their study appears in ACS' journal Biochemistry.
Researchers at the University of Oxford and Progenra, Inc. are pleased to announce the publication of a research article entitled "Activity-Based Chemical Proteomics Accelerates Inhibitor Development for Deubiquitylating Enzymes" that details a novel proteomics based method to detect inhibition of intracellular deubiquitylating enzymes (DUBs).
DARA BioSciences announced today grant approvals by the Internal Revenue Service under the Patient Protection and Affordable Care Act of 2010 for KRN5500 and DB959 in the amount of approximately $500,000 for the calendar year 2009.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ioan Belovarski, MD, MPH 4430 68th St, La Mesa, CA 91942-5837 Ph: (505) 417-2526 | Dr Ioan Belovarski, MD, MPH 333 H St Ste 2080, Chula Vista, CA 91910-5558 Ph: (619) 662-4100 |
News Archive
5N Plus Inc. announced today the closing of a new $250 million senior secured multi-currency revolving credit facility to replace its existing $50 million two-year senior secured revolving facility with National Bank of Canada.
A research team from the University of Liverpool has reached an important milestone towards creating a urine diagnostic test for prostate cancer that could mean that invasive diagnostic procedures that men currently undergo eventually become a thing of the past.
The most poisonous substance on Earth - already used medically in small doses to treat certain nerve disorders and facial wrinkles - could be re-engineered for an expanded role in helping millions of people with rheumatoid arthritis, asthma, psoriasis and other diseases, scientists are reporting. Their study appears in ACS' journal Biochemistry.
Researchers at the University of Oxford and Progenra, Inc. are pleased to announce the publication of a research article entitled "Activity-Based Chemical Proteomics Accelerates Inhibitor Development for Deubiquitylating Enzymes" that details a novel proteomics based method to detect inhibition of intracellular deubiquitylating enzymes (DUBs).
DARA BioSciences announced today grant approvals by the Internal Revenue Service under the Patient Protection and Affordable Care Act of 2010 for KRN5500 and DB959 in the amount of approximately $500,000 for the calendar year 2009.
› Verified 7 days ago
Dr. David Lee Vandenberg, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 435 H St, Chula Vista, CA 91910 Phone: 619-691-7290 Fax: 619-691-7432 | |
Dr. Christy Rosa Mohler, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 435 H St, Chula Vista, CA 91910 Phone: 619-691-7290 Fax: 619-691-7432 | |
Jeffrey Scott Overcash, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 752 Medical Center Ct, Suite 105, Chula Vista, CA 91911 Phone: 619-955-5246 Fax: 619-656-9761 | |
Dr. John A. Siefert, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 435 H St, Chula Vista, CA 91910 Phone: 619-691-7290 | |
Dr. Chad Michael Baasen, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 435 H St, Chula Vista, CA 91910 Phone: 760-725-1614 | |
Kevin Bernard Calhoun, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 751 Medical Center Ct, Chula Vista, CA 91911 Phone: 619-482-5825 | |
Dr. Karrar H. Ali, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 751 Medical Center Ct, Chula Vista, CA 91911 Phone: 619-502-3477 |